The pharmaceutical-focused animal health company is researching the benefits of medical cannabis for companion animals.
CannPal is primarily focused on the development of canine pain medication CPAT-01D, while developing a strong pipeline of other animal pharmaceutical and nutraceutical products.
Completed phase Ia study
During the June quarter 2018, CannPal completed phase Ia of the pharmacokinetic and safety study for CPAT-01, CannPal’s lead drug candidate targeting pain in dogs.
All observational endpoints of the phase Ia study were met.
The initial target dose had an excellent safety profile with no adverse events observed at the dosages administered.
Progressing to phase Ib
CPAT01 showed significant absorption in its current formulation and the success of phase Ia allowed the company to progress into the preparation of the phase Ib study.
Phase Ib is expected to commence in the September quarter and will include 48 dogs of mixed age, sex and breed.
Following the success of phase Ia, CannPal expanded the development program for CPAT-01 to include cats through a research agreement with Eurofins Animal Health Pty Ltd.
The two companies aim to develop a cannabis-derived pain treatment for cats at Eurofins’ research facility in New South Wales.
CPAT-01C (C denotes cats) will leverage knowledge gained from the CPAT-01D (D denotes dogs) studies.
Fully funded for phase II
With $5.11 million in cash at the end of the June quarter 2018, CannPal is fully funded for the planned phase II development of CPAT-01D.
Phase IIa pilot dose determination and population pharmacokinetic studies aim to commence in the December quarter of this year.
CPAT-01D is a pain medication for dogs
CPAT-01D has been developed using active ingredients (both THC and CBD) from the cannabis plant to target symptoms of pain in dogs.
The global canine anti-inflammatory products market has an estimated market size of over US$1 billion.
CPAT-01D is a cost-effective, safe alternative to existing pain medication for dogs with less side effects.
There are little to no pain medications approved for companion animals that are suitable for safe long-term use and non-steroidal anti-inflammatory drugs NSAIDs are widely known for negative side effect profiles.
READ: Cannpal Animal Therapeutics Ltd working with CSIRO in developing cannabinoid treatments for animals
CannPal is also developing nutraceuticals using compounds from the less regulated hemp plant, as part of an early revenue generation strategy.
During the June quarter 2018, CannPal entered into a manufacturing agreement with JayChem Industries Ltd to commence the development work for DermaCann, a treatment for canine skin health.
DermaCann is the first of CannPal’s nutraceutical range and is expected to be market ready as early as mid-2019.
CannPal’s strategy is to position DermaCann as a provider of early potential revenues through alternative regulatory pathways.